REPORT

Regarding the results of the clinical application of the multicomponent peptide bioregulator BreathTIDE PLUS.

The research on "My Real Way" peptide bioregulators was conducted at the Saint Petersburg State Budgetary Healthcare Institution "Municipal Hospital No. 8". The head of the research group is the hospital's chief physician, Doctor of Medical Sciences, and member of the European Academy of Natural Sciences, Irina Savitskaya.

Respiratory diseases are currently among the most prevalent. Chronic obstructive pulmonary disease (COPD), chronic bronchitis, and bronchial asthma are characterized by a continuous increase in morbidity, prevalence, disability, and mortality. According to WHO expert forecasts, by 2020, chronic obstructive pulmonary disease will become the third leading cause of morbidity and mortality worldwide.

BreathTIDE PLUS , a modern, scientifically advanced product – a multi-component peptide bioregulator with a proven mechanism of targeted specific action – helps restore respiratory function, secretion, and mucus transport in the bronchi.

BreathTIDE PLUS (for the broncho-pulmonary system) contains: peptide complex NQ, licorice root (Glycyrrhiza glabra, Radix Liquiritiae), N-acetyl-L-cysteine, selenomethionine, vitamin E, vitamin A, vitamin C, and calcium hydrogen phosphate.

Clinical trials

Clinical trials with the multi-component peptide bioregulator BreathTIDE PLUS were conducted at the St. Petersburg State Budgetary Healthcare Institution "City Hospital No. 8", Nursing Department No. 2, on patients with chronic bronchitis in the exacerbation stage, during October-December 2015.

Medical therapy included antibacterial drugs, measures to improve bronchial patency and bronchoalveolar lavage, non-specific stimulation-enhancing agents, and symptomatic therapy drugs, applied according to the current treatment standard for this category of patients.

BreathTIDE PLUS was administered orally to patients – one capsule twice daily, 20–30 minutes after meals, with sufficient water, for 30–45 days. Contraindication was hypersensitivity to the drug components.

Clinical patient characteristics

• The study involved 8 patients (2 women, 6 men) suffering from chronic bronchitis in the exacerbation stage.
• The average age is 49.6±3.4 years (39–65 years).
• The duration of the disease ranges from 12 to 34 years.
• All patients were smokers, with a smoking history of 10–45 years (mean 19.7±6.2 years) and an average of 20 cigarettes per day.

The control group consisted of 10 patients with similar diagnoses, gender, and age. All study participants signed informed consent forms.

Patients complained of general malaise, periodic fever up to subfebrile levels, fatigue, cough with difficult-to-expectorate sputum, and shortness of breath during exertion and at rest.

Research methods

Evaluation included: dynamics of patient complaints, complete blood count, urinalysis, sputum analysis, and biochemical blood parameters.

Research results

• The use of BreathTIDE PLUS in all patients with chronic bronchitis during exacerbations helped reduce clinical symptoms of inflammation: temperature normalized, general malaise decreased, sputum expectoration improved, cough decreased, and, importantly, shortness of breath lessened.
• The blood leukocyte count and formula normalized in the main group as early as days 8–10 (in the control group – days 12–14).
• Three patients in the control group required a second course of antibiotics, while no patients in the main group needed to be prescribed antibiotics again.
• Clinical symptoms in the main group regressed faster – on average 2.3±0.8 days earlier than in the control group.
• Longer use (40–45 days) of BreathTIDE PLUS provided a more stable and pronounced effect.

No side effects, complications, or addiction were observed.

Conclusion

The results confirm the clinical efficacy of BreathTIDE PLUS and its appropriate use in complex therapy and prevention of respiratory diseases, in conjunction with other pathogenetic and symptomatic treatments.

Source of information: https://myrealway.com/storage/app/media/uploaded-files/CLINICAL%20TRIALS_EN.pdf